Your browser is no longer supported. Please, upgrade your browser.
Krystal Biotech, Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own17.20% Shs Outstand19.72M Perf Week-10.63%
Market Cap1.45B Forward P/E- EPS next Y-3.02 Insider Trans0.00% Shs Float16.51M Perf Month-7.55%
Income-32.20M PEG- EPS next Q-0.58 Inst Own64.40% Short Float7.29% Perf Quarter-9.69%
Sales- P/S- EPS this Y-42.60% Inst Trans0.30% Short Ratio9.30 Perf Half Y61.59%
Book/sh14.81 P/B4.43 EPS next Y4.90% ROA-11.20% Target Price98.80 Perf Year9.45%
Cash/sh12.28 P/C5.35 EPS next 5Y- ROE-11.70% 52W Range37.68 - 87.29 Perf YTD9.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-24.77% Beta1.14
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low74.28% ATR4.66
Employees75 Current Ratio17.80 Sales Q/Q- Oper. Margin- RSI (14)31.42 Volatility7.93% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-70.50% Profit Margin- Rel Volume1.49 Prev Close65.89
ShortableYes LT Debt/Eq0.00 EarningsMar 01 BMO Payout- Avg Volume129.36K Price65.67
Recom1.80 SMA20-13.70% SMA50-13.72% SMA20011.49% Volume193,003 Change-0.33%
Sep-18-20Initiated B. Riley FBR Buy $100
Jun-04-20Initiated Evercore ISI Outperform $90
Sep-24-19Initiated Goldman Neutral $60
Aug-06-19Reiterated H.C. Wainwright Buy $56 → $59
Jun-24-19Reiterated H.C. Wainwright Buy $38 → $56
Jun-24-19Reiterated Chardan Capital Markets Buy $57.50 → $75
May-30-19Initiated Guggenheim Buy
Sep-11-18Initiated Cantor Fitzgerald Overweight $28
May-10-21 08:00AM  
May-03-21 08:00AM  
Apr-29-21 05:41PM  
Apr-27-21 04:35PM  
Apr-26-21 04:05PM  
Apr-19-21 08:00AM  
Mar-30-21 08:00AM  
Mar-29-21 04:30PM  
Mar-24-21 07:00AM  
Mar-01-21 08:37AM  
Feb-23-21 08:00AM  
Feb-08-21 03:55AM  
Feb-03-21 06:50AM  
Feb-02-21 08:51PM  
Jan-04-21 08:00AM  
Dec-10-20 11:44AM  
Nov-24-20 08:00AM  
Nov-09-20 08:00AM  
Oct-16-20 04:10PM  
Oct-08-20 04:10PM  
Sep-24-20 08:00AM  
Sep-09-20 08:00AM  
Aug-25-20 08:00AM  
Aug-18-20 08:19AM  
Aug-17-20 04:01PM  
Aug-11-20 08:54AM  
Aug-10-20 08:00AM  
Jul-30-20 08:00AM  
Jul-28-20 04:44PM  
Jul-20-20 08:00AM  
Jun-26-20 11:20AM  
Jun-08-20 04:01PM  
May-25-20 10:00AM  
May-19-20 06:53PM  
May-18-20 09:57PM  
May-14-20 08:00AM  
May-04-20 08:00AM  
Apr-21-20 08:05AM  
Apr-01-20 08:24AM  
Mar-10-20 08:00AM  
Feb-25-20 08:21AM  
Feb-21-20 08:00AM  
Jan-24-20 08:00AM  
Jan-21-20 08:00AM  
Jan-02-20 12:28PM  
Dec-23-19 12:00PM  
Dec-14-19 09:42PM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-03-19 08:50AM  
Nov-26-19 08:00AM  
Nov-14-19 10:00AM  
Nov-04-19 08:00AM  
Oct-30-19 05:23PM  
Oct-29-19 08:00AM  
Oct-10-19 08:00AM  
Oct-04-19 08:38AM  
Sep-30-19 08:00AM  
Sep-27-19 08:00AM  
Sep-04-19 08:00AM  
Aug-27-19 04:05PM  
Aug-14-19 03:12PM  
Aug-05-19 08:00AM  
Jul-01-19 09:05AM  
Jun-27-19 11:18AM  
Jun-25-19 01:15PM  
Jun-24-19 04:31PM  
Jun-14-19 08:00AM  
May-15-19 08:00AM  
May-06-19 08:00AM  
Apr-29-19 08:00AM  
Mar-29-19 08:00AM  
Mar-12-19 08:00AM  
Mar-07-19 08:58AM  
Mar-06-19 08:00AM  
Mar-04-19 08:00AM  
Mar-01-19 08:00AM  
Feb-22-19 08:00AM  
Jan-18-19 01:57PM  
Jan-15-19 08:00AM  
Dec-19-18 08:00AM  
Nov-21-18 07:55AM  
Nov-20-18 08:00AM  
Nov-05-18 08:00AM  
Oct-23-18 04:01PM  
Oct-22-18 07:15PM  
Oct-18-18 06:03PM  
Oct-17-18 04:01PM  
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krishnan SumaChief Operating OfficerSep 17Sale46.3719,157888,3581,836,064Sep 17 06:35 PM
Krishnan SumaChief Operating OfficerSep 16Sale46.4514,891691,7171,855,221Sep 17 06:35 PM
Krishnan SumaChief Operating OfficerSep 15Sale46.3015,952738,5541,870,112Sep 17 06:35 PM
Krishnan SumaChief Operating OfficerJun 15Sale43.5050,0002,174,7751,886,064Jun 17 04:14 PM
Krishnan Krish SPresident and CEOMay 18Sale57.8823,1611,340,5211,886,462May 19 05:01 PM
Krishnan Krish SPresident and CEOMay 15Sale58.3626,8391,566,3861,909,623May 19 05:01 PM